Francesco Passiglia

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Francesco Passiglia, Giuseppe Bronte, Viviana Bazan et al. · Oncotarget · 2016 · 165 citations · Full text

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri et al. · European Journal of Cancer · 2020 · 145 citations · Full text

First-line Pembrolizumab, Medicine, Pathology +6

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 132 citations · Full text

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 95 citations · Full text

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 87 citations · Full text

Advanced Nsclc, Oncology, First-line Pembrolizumab Effectiveness +6